First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial. This is an ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results